Global Cell Line Development Market Size, Forecast, and Trend Highlights Over 2021 – 2031
|
Base Year |
2021 |
|
Forecast Year |
2022-2031 |
|
CAGR |
~12.39% |
|
Base Year Market Size (2021) |
USD 4,588.5 Million |
|
Forecast Year Market Size (2031) |
USD 14,679.1 Million |
The global cell line development market is estimated to garner a revenue of USD 14,679.1 Million by the end of 2031 by growing at a CAGR of 12.39% over the forecast period, i.e., 2022 – 2031. Further, the market generated a revenue of USD 4,588.5 Million in the year 2021. The growth of the market can be attributed to the growing demand for monoclonal antibodies. These antibodies help to stimulate immune system. Thus they are extensively used for treating cancer, migraines, and more. Further, rising burden of cancer is expected to boost the market growth. According to the World Health Organization, Cancer is the most common cause of death worldwide, accounting for almost 10 million fatalities in 2020, or nearly one in every six deaths.
Get more information on this report: Request Sample PDF
Moreover, rising need for vaccine production is anticipated to fuel the growth of the cell line development market. The cell line development technology is used in manufacturing various vaccines in order to treat viral infection such as HIV, influenza, and more. These vaccines prove to stimulate body immune system. Besides this, cell line technology has successful manufactured vaccine which could treat mild or moderate coronavirus. For a novel monoclonal antibody to treat COVID-19 that prevents the activity of the omicron variant, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) in February 2022.
Global Cell Line Development Market: Growth Drivers and Challenges
Growth Drivers
- Rising Burden of Osteoporosis
According to the International Osteoporosis Foundation, every year, osteoporosis causes more than 8.9 million fractures worldwide, culminating in an osteoporosis fracture every 3 seconds.
To deal with growing osteoporosis monoclonal antibodies are prepared which is known are stimulating antibodies in patient. Hence owing to this the market is expected to boost in the forecast period.
- Growing Risk of Coronavirus
As of February 2022, there had been approximate 5 million confirmed deaths due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, which has caused over 400 million cases.
- Increasing Risk of Cancer Causing Disease
According to the World Health Organization, about 30% of cancer cases in low- and lower-middle-income nations are caused by cancer-causing diseases such the human papillomavirus (HPV) and hepatitis.
- Growing Nervous Systems Disorder Cases
According to the European Academy of Neurology, over the past 30 years, the incidence of deaths from neurological disorders has climbed by approximately 40%, with 1 in 3 persons experiencing a neurological ailment at some point in their lives.
- Cell Line Development Based On Mammalian Cell Culture
Mammalian cell culture has recently become essential to the biomanufacturing of viral vaccines and therapeutic proteins. Through viral infection, these cells create vaccines, and through genetic engineering, they produce therapeutic proteins.
Challenges
- Inability to Produce or Develop a Stable and Authentic Cell
- Low Transfection Efficiency
- Integration Frequency
Stable cell lines are a crucial laboratory tool for screening experimental medications, researching gene function, and generating therapeutic proteins because they express significant amounts of the protein of interest. However, a variety of elements, including the use of a DNA vector, reagents, the choice of cell lines, and the transfection technique, are equally crucial in creating a stable cell line. Additionally, the stability of cell lines will suffer from any modifications or adjustments to these variables. Hence this factor could hinder the growth of the market.
The global cell line development market is segmented and analysed for demand and supply by cell type into CHO cells, BHK 21 cells, NSO cells, murine C127 cells, NIH3T3 cells, L929 cells, and others. Out of which, BHK 21 cells segment is anticipated to garner the revenue of USD 2,455.4 Million by the end of 2031, by growing at a highest CAGR of 12.84% during the forecast period. In 2021 the revenue of BHK 21 cells segment stood at USD 737.8 Million. Increasing cases of rabies is expected to boost the market growth. BHK 21 cells are most frequently used cells lines. They are extensively used for treating rabies. The World Organization for Animal Health use these BHK21 cells in the regular diagnosis of rabies. To thrive in serum- or animal-component-free cell medium for the manufacture of rabies vaccines, BHK21 cells appear to have already undergone the necessary adaptations. Additionally CHO cells segment is anticipated to garner the largest revenue of USD 5,396.4 Million by the end of 2031.
Global Cell Line Development Market Regional Synopsis
Regionally, the global cell line development market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in Asia Pacific is projected to hold the market share of USD 3,945.1 Million by the end of 2031, up from a revenue of USD 1,166.9 Million in the year 2021. Further, the market in Asia Pacific is expected to grow at the highest CAGR of 13.02% over the forecast period. Besides this the market in North America is projected to garner the largest revenue of USD 5,086.7 Million by the end of 2031, backed by increasing investments and funds made available to manufacturing businesses and academic & research institutions to develop cell line-based end products like precision medicine and other treatments. In 2018, the National Institutes of Health's All of Us Research Program funded Genome Centers to generate genotype sequencing data from bio samples. To aid researchers in their quest to better understand how genetics, environment, and lifestyle choices affect health outcomes, they seek to create a varied network of more than 1 million participant partners across the US. In the upcoming years, it is anticipated that these factors will encourage market expansion.
The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Market Segmentation
Our in-depth analysis of the global cell line development market includes the following segments:
|
By Product |
|
|
By Cell Type |
|
|
By Application |
|
|
By Industry |
|
Top Featured Companies Dominating The Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global cell line development market that are included in our report are Lonza Group Ltd., Thermo Fisher Scientific, Corning Incorporated, General Electric Company, Sartorius AG, Selexis SA, Merck KGaA, WuXi AppTec, and others. The market research report also covers an in-depth analysis of the academia organizations who are associated with cell line development, the profiling of which includes organizations such as American Type Culture Collection (ATCC), and European Collection of Authentic Cell Cultures.
